-

CareDx To Present at the 2023 Cantor Global Healthcare Conference

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the 2023 Cantor Global Healthcare Conference.

CareDx’s management is scheduled to present at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023, at 7:20 AM PT / 10:20 AM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s investor relations website at: investors.caredxinc.com.

About CareDx – The Transplant Company™

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Contacts

Media Relations
Anna Czene
818-731-2203
aczene@caredx.com

Investor Relations
Greg Chodaczek
Investor@caredx.com

CareDx, Inc.

NASDAQ:CDNA

Release Versions

Contacts

Media Relations
Anna Czene
818-731-2203
aczene@caredx.com

Investor Relations
Greg Chodaczek
Investor@caredx.com

More News From CareDx, Inc.

CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx will partner with TC BioPharm to perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial. AlloCell has been used in ten prior cell therapy clin...

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Jefferies London Healthcare Conference 2024 in London, UK. Presentation on Tuesday, November 19 at 9:00 AM GMT/4:00 AM EST...

CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Total revenue of $82.9 million increased 23% year-over-year Testing Services volume of 44,600 tests increased 16% year-over-year GAAP net loss of $7.4 million, non-GAAP net income of $8.0 million, and positive adjusted EBITDA of $6.9 million, a significant improvement from the third quarter 2023 Cash flow from...
Back to Newsroom